Classical tissue engineering strategies are patient-specific, thus clearly associated with inherent limits: a time-consuming graft production and a complex/costly production. Most importantly those cell-based strategy only allows for autologous use of the generated grafts. Here, we will validate the large-scale production and pre-clinical performance of a unique bone graft substitute. If successful, our cell-free cartilage product will bypass limits of existing tissue engineered strategies.
Menu